This heterogeneity may possibly provide an explanation for the apparent distribution of serum MFAP4 into two distinct groups in the non-STEMI patients and larger studies with more patients within each category and with more detailed information about the type of myocardial infarction are warranted. Here, MFAP4 is linked to myocardial infarction.